CheckMate 067: Phase 3 trial of nivolumab in melanoma - European Medical Journal

Continue

CheckMate 067: Phase 3 trial of nivolumab in melanoma

Oncology
University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naive patients with advanced melanoma.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.